SCHEMBL1048847

SCHEMBL1048847

O=C(O)c1n[nH]c2ncccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP3A4 P08684 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
BLM P54132 1/20 0.47
AGER Q15109 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CAMKK2 Q96RR4 1/20 0.44
CYP1A2 P05177 1/20 0.42
HAO1 Q9UJM8 1/20 0.41
MAP2K1 Q02750 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
FLT3 P36888 1/20 0.41
CCNA1 P78396 1/20 0.41
MAPK10 P53779 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29623160 1.00 KDM4E (0.47) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL4770342 0.88 KDM4E (0.43) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL28098788 0.87 MAP2K1 (0.41) KDM4EALDH1A1CAMKK2MAP2K1CCNA2
SCHEMBL5924436 0.84 MAP2K1 (0.43) KDM4EALDH1A1CAMKK2CYP1A2MAP2K1
SCHEMBL1384475 0.84 CAMKK2 (0.46) KDM4EALDH1A1CAMKK2MAP2K1MAPK10
SCHEMBL29732854 0.84 CAMKK2 (0.46) KDM4EALDH1A1CAMKK2MAP2K1MAPK10
SCHEMBL5924295 0.84 KDM4E (0.40) KDM4EALDH1A1CAMKK2MAP2K1CCNA2
SCHEMBL5315499 0.82 CCNA2 (0.39) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL19150307 0.82 AXL (0.37) KDM4EMAPTALDH1A1CAMKK2MAP2K1
SCHEMBL1554784 0.81 KDM4E (0.60) KDM4EL3MBTL1ALDH1A1TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12429777-B2 Photoresist stripper composition for manufacturing display LTC CO., LTD. (KR) 2025-09-30 US claimed
US-20220404710-A1 PHOTORESIST STRIPPER COMPOSITION FOR MANUFACTURING DISPLAY LTC CO., LTD. (KR) 2022-12-22 US claimed
EP-4063957-A1 PHOTORESIST STRIPPER COMPOSITION FOR MANUFACTURING DISPLAY LTC Co. Ltd. (KR) 2022-09-28 EP claimed
CN-114651215-A Photoresist stripping liquid composition for manufacturing display LTC有限公司 2022-06-21 CN claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-20260022131-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-01-22 US disclosed
US-12473302-B2 4-phenylpiperidines, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-11-18 US disclosed
US-12429777-B2 Photoresist stripper composition for manufacturing display LTC CO., LTD. (KR) 2025-09-30 US disclosed
US-20240287092-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-08-29 US disclosed
US-20240150345-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF PHARMARON UK LTD. (GB) 2024-05-09 US disclosed
US-11919913-B2 4-phenylpiperidines, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-03-05 US disclosed
US-7514463-B2 Lonidamine analogues and their use in male contraception and cancer treatment UNIVERSITY OF KANSAS (US) 2009-04-07 US disclosed
US-20080308005-A1 Non-Aqueous Pigment Dispersions Using Dispersion Synergists AGFA GRAPHICS NV (BE) 2008-12-18 US disclosed
EP-1814883-A1 BICYCLIC INHIBITORS OR RHO KINASE Vertex Pharmaceuticals Incorporated (US) 2007-08-08 EP disclosed
EP-1786424-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT The University of Kansas (US) 2007-05-23 EP disclosed
US-20060122185-A1 Bicyclic inhibitors of Rho kinase VERTEX PHARMACEUTICALS INCORPORATED 2006-06-08 US disclosed
WO-2006058120-A1 BICYCLIC INHIBITORS OR RHO KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 WO disclosed
US-20060047126-A1 Lonidamine analogues and their use in male contraception and cancer treatment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-03-02 US disclosed
WO-2006023704-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT UNIVERSITY OF KANSAS (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287092-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE HTR3C, HRH4, DRD3 KDM4E 1319/4885MAPT 3601/4885L3MBTL1 3372/4885
US-12473302-B2 4-phenylpiperidines, their preparation and use HTR3C, HRH4, DRD3 KDM4E 1319/4885MAPT 3601/4885L3MBTL1 3372/4885
US-11919913-B2 4-phenylpiperidines, their preparation and use HTR3C, HRH4, CYP4F3 KDM4E 1279/4885MAPT 3565/4885L3MBTL1 3481/4885
US-20060122185-A1 Bicyclic inhibitors of Rho kinase ROCK1, ROCK2, RHOA KDM4E 1635/4885MAPT 719/4885L3MBTL1 2857/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH KDM4E 3565/4885MAPT 3782/4885L3MBTL1 1163/4885
US-20060047126-A1 Lonidamine analogues and their use in male contraception and cancer treatment TRAP1, HSPE1, HSF1 KDM4E 1905/4885MAPT 3368/4885L3MBTL1 523/4885
US-20240150345-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF EIF2AK4, GCN1, CLN6 KDM4E 4187/4885MAPT 477/4885L3MBTL1 1921/4885
US-20260022131-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE CLN6, NR2E3, CBR3 KDM4E 3025/4885MAPT 3951/4885L3MBTL1 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.